Clinical Study of Weifuchun Treatment on Gastric Cancer
Gastric Cancer (Diagnosis)
About this trial
This is an interventional treatment trial for Gastric Cancer (Diagnosis) focused on measuring Weifu Chun, Gastric Cancer, Clinical Efficacy, randomized clinical trial, mechanism
Eligibility Criteria
Inclusion Criteria: Patients should be aged between 18 and 70 years old (including 18 and 70 years old) and their gender is not limited. Pathological diagnosis of gastric malignant tumor; The pathological types were adenocarcinoma, tubular adenocarcinoma, mucous adenocarcinoma and sig-ring cell carcinoma (including adenocarcinoma and some sig-ring cell carcinoma); Patients were willing to receive chemotherapy (oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, or Ticeo monotherapy regimen). The patient was willing to receive weifunchun treatment. Exclusion Criteria: Incomplete pathological diagnostic data; Patients with severe heart, lung, liver, kidney (creatinine greater than the upper limit of the normal range), endocrine, hematopoietic system or psychiatric diseases were considered not suitable for the study group; Pregnant or lactating women, as well as pregnant persons who may not have taken effective contraceptive measures; People who are allergic (allergic to two or more kinds of food, drugs, etc.) or are allergic to known ingredients of the medicine; Patients with other medical conditions that interfere with the trial and are deemed unsuitable for inclusion in the trial by the investigator; Patients enrolled in other clinical trials within the last 1 month.
Sites / Locations
Arms of the Study
Arm 1
Other
Clinical Study of Weifuchun Treatment on Gastric Cancer
72 patients with gastric cancer were randomly divided into a treatment group of 36 cases and a control group of 36 cases. The treatment group received combination chemotherapy with Weifuchun tablets, while the control group received monotherapy chemotherapy.